- Investing.com
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Metrics to compare | PEPG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPEPGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −4.5x | −0.5x | |
PEG Ratio | −0.05 | −0.11 | 0.00 | |
Price/Book | 0.8x | 3.6x | 2.6x | |
Price / LTM Sales | - | 11.3x | 3.2x | |
Upside (Analyst Target) | - | 98.1% | 45.6% | |
Fair Value Upside | Unlock | −4.3% | 5.3% | Unlock |